Banking on ATM as a new target in metabolic syndrome  by Shoelson, Steven E.
Loffing, J., Vallon, V., Loffing-Cueni, D., Aregger,
F., Richter, K., Pietri, L., Bloch-Faure, M., Hoen-
derop, J.G., Shull, G.E., Meneton, P., and Kais-
sling, B. (2004). J. Am. Soc. Nephrol. 15, 2276–
2288.
O’Reilly, M., Marshall, E., Macgillivray, T., Mit-
tal, M., Xue, W., Kenyon, C.J., and Brown,
R.W. (2006). J. Am. Soc. Nephrol. 17, 2402–
2413.
Schultheis, P.J., Lorenz, J.N., Meneton, P.,
Nieman, M.L., Riddle, T.M., Flagella, M., Duffy,
J.J., Doetschman, T., Miller, M.L., and Shull,
G.E. (1998). J. Biol. Chem. 273, 29150–
29155.
Wilson, F.H., Disse-Nicodeme, S., Choate, K.A.,
Ishikawa, K., Nelson-Williams, C., Desitter, I.,
Gunel, M., Milford, D.V., Lipkin, G.W., Achard,
J.M., et al. (2001). Science 293, 1107–1112.
Wilson, F.H., Kahle, K.T., Sabath, E., Lalioti, M.D.,
Rapson, A.K., Hoover, R.S., Hebert, S.C.,
Gamba, G., and Lifton, R.P. (2003). Proc. Natl.
Acad. Sci. USA 100, 680–684.
Xu, B., English, J.M., Wilsbacher, J.L., Stippec,
S., Goldsmith, E.J., and Cobb, M.H. (2000). J.
Biol. Chem. 275, 16795–16801.
DOI 10.1016/j.cmet.2006.10.007
P R E V I E W SBanking on ATM as a new target in metabolic syndrome
In this issue of Cell Metabolism, Semenkovich and his colleagues show that ATM, a protein well known for its roles in the
cellular response to DNA breaks, may also be linked to metabolic and cardiovascular diseases (Schneider et al., 2006). ATM
seemingly does this by inhibiting JNK, a stress kinase involved in inflammation with related effects in insulin resistance and
atherosclerosis. In an interesting twist, the authors show that chloroquine, an antimalarial drug, also activates ATM, which
inhibits JNK, and improves insulin sensitivity and cardiovascular effects. These findings provide potential new insights into
the pathogenesis and treatment of metabolic syndrome.Ataxia telangiectasia (A-T) is a progres-
sive, neurogenerative disease that typi-
cally presents itself in the first decade
with delayed development of motor
skills, including poor balance and slurred
speech. About 20% of patients with A-T
develop cancer, most often acute lym-
phocytic lymphoma or leukemia, and
many are immunodeficient and sensitive
to radiation. A-T may be associated
with varying degrees of insulin resistance
and a relatively mild impairment in glyce-
mic control (Ristow, 2004).
A-T is incurable and at this point there
is not even a good way to slow progres-
sion of the disease. A-T is caused by
mutations in Atm (ataxia telangiectasia
mutated), the gene that encodes ATM
(Savitsky et al., 1995). Over 500 muta-
tions causing A-T have been identified;
most affected individuals are compound
heterozygotes. ATM is a large, modular
protein with a serine/threonine kinase
domain and a binding site for the tumor
suppressor, p53. ATM senses breaks in
double-stranded DNA and coordinates
cell cycle checks prior to repair.
Schneider et al. (2006) examine the re-
lationship between ATM deficiency and
metabolism in mice, looking specifically
at aspects of the metabolic syndrome
such as insulin resistance, adiposity,
blood pressure, circulating cholesterol
and lipid levels, andatherosclerosis.Con-CELL METABOLISM : NOVEMBER 2006vincingdata show that evena50%reduc-
tion in gene dosage and probably protein
concentration affects a large number of
metabolic parameters. Fat mass, blood
pressure, fasting, and postchallenge glu-
cose and insulin concentrationswere ele-
vated, insulin sensitivity was decreased,
and atherosclerotic lesions were more
prominent in Atm2/+ and Atm2/2mice.
These pathophysiological changes
were accompanied by concordant bio-
chemical changes in a variety of tissues
and cell types. For example, decreased
insulin signaling accompanied reduced
ATM activity in muscle, liver, and isolated
macrophages. In aorta, there were de-
creases in p38, AKT, and ERK activities,
but increases in inhibited IRS-1 and
JNK activity, a serine/threonine kinase
that inhibits IRS-1 (Figure 1).
The investigators next took advantage
of an interesting in vitro finding, that the
antimalarial chloroquine stimulates ATM
activity in the absence of DNA strand
breaks (Bakkenist and Kastan, 2003).
They took this a step further by using a
small doseofchloroquine toactivateATM
inmice, which decreased atherosclerotic
lesion area in Apoe2/2 mice and insulin
and glucose levels in ob/ob and db/db
mice. Consistent with ATM as the phar-
macological target, chloroquine treatment
decreased JNK activity in macrophages
from Atm+/+ but not Atm2/2 mice, andimproved blood pressure and glycemic
control in Atm+/+ but not Atm2/2mice.
It is noteworthy that a 50% reduction in
gene dose inAtm2/+mice significantly af-
fected several metabolic parameters,
and it is undoubtedly important from a
mechanistic viewpoint that many of the
parameters studied in heterozygous and
homozygous mice were equivalently
affected. This is in distinct contrast with
what is seen in patients with A-T, where
both alleles are mutated and heterozy-
gous carriers are unaffected. It is doubtful
that drugs such as chloroquine would
benefit patients with A-T. Heterozygous
carriers do however have an increased
risk for developing certain cancers, most
notably breast cancer (Swift et al., 1987).
These new findings (Schneider et al.,
2006) suggest that drugs such as chloro-
quine that upregulate ATM activity might
provide prophylactic benefit to carriers
by decreasing cancer risk. Of course
this needs to be formally tested, but this
could be important for a substantial por-
tion of the population, as 0.5%–2.0%
are suspected of being carriers.
The increase in metabolic and cardio-
vascular abnormalities seen in Atm2/+
mice predicts a greater than previously
appreciated risk for diabetes, hyperten-
sion, and cardiovascular disease in A-T
family members and other carriers. One
would expect that these individuals too337
P R E V I E W SFigure 1. ATM inhibition of inflammatory signaling
JNK/AP-1 and IKKb/NF-kB pathways are activated in the metabolic syndrome, possibly by proinflammatory
(e.g. TNF-a, IL-1b) or pattern recognition (Toll or AGE) receptors (TNFR, IL1R, TLR, or RAGE, respectively),
reactive oxygen (ROS) or ER stress, or an isoform of PKC. JNK phosphorylation of IRS-1 inhibits normal insulin
signaling, whereas JNK activation of AP-1 induces the expression of Egr-1 and lipoprotein lipase (LPL). ATM
inhibition of JNK would inhibit the inhibitor, i.e. improve insulin signaling, and diminish LPL production to
potentially decrease cardiovascular risk. Concomitant inhibition of NF-kB would provide a broad benefit, as
many proteins involved in the pathogenesis of insulin resistance, atherosclerosis and metabolic syndrome
are NF-kB targets.would benefit from a chloroquine-like
drug that activates ATM. But perhaps
most intriguing are the chloroquine ef-
fects in mice that are wild-type for Atm.
Chloroquine treatment decreased glu-
cose levels, blood pressure, and vascu-
lar lesion area in the Apoe-/- mice, and
decreased glucose levels in ob/ob as
well as db/dbmice. If these results trans-
late to humans, then much greater seg-
ments of the population might benefit,
as 25%–30% of American adults are es-
timated to be obese or have the meta-
bolic syndrome.
Chloroquine is used to treat malaria
and occasionally, rheumatoid arthritis
and discoid lupus, although the latter dis-
orders require higher doses. Schneider
et al. (2006) use a low dose of chloro-
quine to improve metabolic and cardio-
vascular parameters. But these are338chronic diseases that in humans would
require long-term treatment. While
many adverse reactions have been at-
tributed to chloroquine, perhaps themost
disturbing is visual impairment. Retinop-
athy can be permanent and can continue
to progress even after the drug has been
discontinued. These points suggest that
chloroquine could be used in clinical tri-
als as a proof of principle, but it is less
likely that chloroquine will find itself in
the clinicians’ armamentarium as a new
treatment in patients with metabolic
syndrome. Other drugs with less toxicity
that also activate ATM, providing this is
validated as chloroquine’s mechanism
in these disorders, might furnish an inter-
esting new avenue for treatment.
How does ATM impact insulin resis-
tance and atherosclerosis? The authors
provide two cell-autonomous possibili-ties that both look to ATM’s ability to
inhibit JNK (Figure 1). For insulin resis-
tance, they show that less JNK activity
decreases levels of inhibitory IRS-1
Ser307 phosphorylation, which would
improve insulin action; for atherosclero-
sis they suggest that decreased JNK
activity decreases lipoprotein lipase ex-
pression. While these are plausible ex-
planations, their scope may be too lim-
ited. IKKb/NF-kB operates in parallel
with JNK/AP-1, downstream from pro-
inflammatory inputs. In chronic condi-
tions such as insulin resistance and
cardiovascular disease, it appears that
a balance is maintained between these
pathways. This predicts that in addi-
tion to inhibiting JNK, ATM activation
would inhibit NF-kB. Given the estab-
lished roles for NF-kB in the develop-
ment and progression of insulin resis-
tance and atherosclerosis (Shoelson
et al., 2006; Hansson and Libby, 2006),
these too could be fruitful areas for future
research.
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